Bristol Myers Squibb (BMY) Cost of Revenue (2016 - 2026)

Bristol Myers Squibb has reported Cost of Revenue over the past 18 years, most recently at $3.4 billion for Q1 2026.

Quarterly Cost of Revenue rose 12.79% to $3.4 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $14.3 billion through Mar 2026, up 1.82% year-over-year, with the annual reading at $13.9 billion for FY2025, 0.23% changed from the prior year.
Cost of Revenue was $3.4 billion for Q1 2026 at Bristol Myers Squibb, down from $4.1 billion in the prior quarter.
Over five years, Cost of Revenue peaked at $4.8 billion in Q4 2024 and troughed at $2.4 billion in Q3 2022.
The 5-year median for Cost of Revenue is $2.9 billion (2024), against an average of $3.1 billion.
Year-over-year, Cost of Revenue soared 75.3% in 2024 and then fell 14.86% in 2025.
A 5-year view of Cost of Revenue shows it stood at $2.6 billion in 2022, then grew by 5.86% to $2.7 billion in 2023, then soared by 75.3% to $4.8 billion in 2024, then dropped by 14.86% to $4.1 billion in 2025, then decreased by 16.5% to $3.4 billion in 2026.
Per Business Quant, the three most recent readings for BMY's Cost of Revenue are $3.4 billion (Q1 2026), $4.1 billion (Q4 2025), and $3.4 billion (Q3 2025).

Peer Comparison